Based on our findings, we proposed that targeting the 12 identified shared genes could be a promising approach for treating T2DM and OA by modulating the p53, IL‐17, NF‐kB and MAPK signalling pathways while regulating ferroptosis and immunity. Here, IL17A is linked to type 2 diabetes mellitus.